PDPN and neoplasm: It has been reported that, by antibodies that block platelet aggregation activity through podoplanin domains, the role of podoplanin domains in platelet aggregation was confirmed in the CLEC-2 binding and tumor emboli formation, concluding that the inhibition of these domains prevents podoplanin-mediated tumor growth and metastasis [123].